$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Metformin Association with Lower Prostate Cancer Recurrence in Type 2 Diabetes: a Systematic Review and Meta-analysis 원문보기

Asian Pacific journal of cancer prevention : APJCP, v.16 no.2, 2015년, pp.595 - 600  

Hwang, In Cheol (Department of Family Medicine, Gachon University Gil Medical Center) ,  Park, Sang Min (Department of Family Medicine and Biomedical Sciences, Seoul National University College of Medicine) ,  Shin, Doosup (Department of Education and Research, Seoul National University College of Medicine) ,  Ahn, Hong Yup (Department of Statistics, Dongguk University) ,  Rieken, Malte (Department of Urology, University Hospital Basel) ,  Shariat, Shahrokh F. (Department of Urology, Medical University of Vienna)

Abstract AI-Helper 아이콘AI-Helper

Background: Accumulating evidence suggests that metformin possesses anticarcinogenic properties, and its use is associated with favorable outcomes in several cancers. However, it remains unclear whether metformin influences prognosis in prostate cancer (PCa) with concurrent type 2 diabetes (T2D). Ma...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

제안 방법

  • All potentially relevant articles were independently evaluated by two investigators (IC Hwang and D Shin); disagreements were resolved by consensus or consultation with a third author (SM Park). The following data were abstracted from each study: first author, year of publication, country, study design, site of cancer, clinical setting, study period, length of follow-up, number of patients in each group, outcome assessed, risk estimates with corresponding 95% CIs, and variables adjusted. We used the Newcastle-Ottawa Scale (NOS) to assess the methodological quality.
  • , author replies, conference abstracts). To be included in the meta-analysis, the studies had to provide a risk estimate (e.g., hazard ratio, relative risk [RR], odds ratio) and measure of precision (e.g., confidence interval [CI]) for the impact of metformin use on outcomes (recurrence, progression, CSM, or ACM). We excluded data on castration-resistant PCa, which was reported by only one paper (Spratt et al.

데이터처리

  • Publication bias was assessed using the Begg’s rank correlation test (Begg and Mazumdar, 1994).

이론/모형

  • 92. Summary RR estimates were derived using the method of DerSimonian and Laird (DerSimonian and Laird, 1986).
본문요약 정보가 도움이 되었나요?

참고문헌 (43)

  1. Allott EH, Abern MR, Gerber L, et al (2013). Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis, 16, 391-7. 

  2. Azvolinsky A (2014). Repurposing to fight cancer: the metformin-prostate cancer connection. J Natl Cancer Inst, 106, dju030. 

  3. Bansal D, Bhansali A, Kapil G, et al (2013). Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis, 16, 151-8. 

  4. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101. 

  5. Ben Sahra I, Laurent K, Giuliano S, et al (2010). Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res, 70, 2465-75. 

  6. Ben Sahra I, Laurent K, Loubat A, et al (2008). The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene, 27, 3576-86. 

  7. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M (2005). Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health, 5, 36. 

  8. Bonanni B, Puntoni M, Cazzaniga M, et al (2012). Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol, 30, 2593-600. 

  9. Casa AJ, Dearth RK, Litzenburger BC, et al (2008). The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci, 13, 3273-87. 

  10. Conteduca V, Di Lorenzo G, Bozza G, et al (2013). Metabolic syndrome as a peculiar target for management of prostate cancer patients. Clin Genitourin Cancer, 11, 211-20. 

  11. Currie CJ, Poole CD, Gale EA (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 52, 1766-77. 

  12. Currie CJ, Poole CD, Jenkins-Jones S, et al (2012). Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care, 35, 299-304. 

  13. Decensi A, Puntoni M, Goodwin P, et al (2010). Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila), 3, 1451-61. 

  14. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. 

  15. Emami Riedmaier A, Fisel P, Nies AT, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci, 34, 126-35. 

  16. Evans JM, Donnelly LA, Emslie-Smith AM, et al (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ, 330, 1304-5. 

  17. Freedland SJ, Aronson WJ (2009). Dietary intervention strategies to modulate prostate cancer risk and prognosis. Curr Opin Urol, 19, 263-7. 

  18. Garcia JA, Danielpour D (2008). Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther, 7, 1347-54. 

  19. Giovannucci E, Harlan DM, Archer MC, et al (2010). Diabetes and cancer: a consensus report. CA Cancer J Clin, 60, 207-21. 

  20. He XX, Tu SM, Lee MH, Yeung SC (2011). Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol, 22, 2640-5. 

  21. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58. 

  22. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res, 69, 7507-11. 

  23. Jiralerspong S, Palla SL, Giordano SH, et al (2009). Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol, 27, 3297-302. 

  24. Kaushik D, Karnes RJ, Eisenberg MS, et al (2014). Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol, 32, 1-7. 

  25. Landman GW, Kleefstra N, van Hateren KJ, et al (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 33, 322-6. 

  26. Li C, Zhao G, Okoro CA, et al (2013). Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: findings from the 2009 behavioral risk factor surveillance system. Diabetes Care, 36, 1569-76. 

  27. Libby G, Donnelly LA, Donnan PT, et al (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 32, 1620-5. 

  28. Margel D, Urbach DR, Lipscombe LL, et al (2013). Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol, 31, 3069-75. 

  29. Niraula S, Dowling RJ, Ennis M, et al (2012). Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat, 135, 821-30. 

  30. Niraula S, Pond G, de Wit R, et al (2013). Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J, 7, 74-81. 

  31. Patel T, Hruby G, Badani K, et al (2010). Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology, 76, 1240-4. 

  32. Peehl DM, Stamey TA (1986). Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol, 22, 82-90. 

  33. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28. 

  34. Pollak MN (2012). Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov, 2, 778-90. 

  35. Rieken M, Kluth LA, Xylinas E, et al (2014). Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. World J Urol, 32, 999-1005. 

  36. Sarma AV, Jaffe CA, Schottenfeld D, et al (2002). Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. Urology, 59, 362-7. 

  37. Sciacca L, Vigneri R, Tumminia A, et al (2013). Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis, 23, 808-15. 

  38. Sikka S, Chen L, Sethi G, Kumar AP (2012). Targeting PPARgamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Res, 2012, 968040. 

  39. Snyder CF, Stein KB, Barone BB, et al (2010). Does pre-existing diabetes affect prostate cancer prognosis? a systematic review. Prostate Cancer Prostatic Dis, 13, 58-64. 

  40. Song CW, Lee H, Dings RP, et al (2012). Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Sci Rep, 2, 362. 

  41. Spratt DE, Zhang C, Zumsteg ZS, et al (2013). Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol, 63, 709-16. 

  42. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA, 283, 2008-12. 

  43. Suissa S, Azoulay L (2012). Metformin and the risk of cancer: 

저자의 다른 논문 :

LOADING...

관련 콘텐츠

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로